These data is in agreement with previous observations of enhanced tau pathology in mutant tau-expressing mice injected with Aβ42 peptides [39] or co-expressing mutant AβPP or BRI2 in their brains [40]–[42], supporting the hypothesis that amyloidosis facilitates tauopathy in AD. This evidence concerns the gene MAPT and amyloidosis.